VITAEUM

From the public record

Name	VITAEUM
Tagline	Spatial physiology infrastructure building a non-diagnostic measurement layer for longevity, pharma, clinical, and wellness. [VITAEUM, retrieved 2026]
Headquarters	Scottsdale, Arizona, US
Founded	2022
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed

Links

From the public record

• Website: https://www.vitaeum.us/
• LinkedIn: https://www.linkedin.com/company/vitaeum
• Wellness App: https://www.vitaeumwellness.com/wellness

The Short Version

From the public record VITAEUM is constructing a non-diagnostic measurement layer for human physiology, an early-stage bet that the future of longevity, clinical, and wellness markets hinges on standardized, longitudinal data captured via infrared imaging. The company’s wedge is a combination of patent-pending technology and a regulatory-first strategy, positioning its Predictive Infrared Intelligence™ (PII™) platform as the infrastructure for a new category called spatial physiology [VITAEUM, retrieved 2026]. Founder Mike Maunu, who has prior entrepreneurial experience in non-invasive infrared-based health technologies through Oxygen4Life™ Inc., is leading the effort to define this regulatory category, with a stated goal of bridging episodic diagnostics with outcome-aware care [LinkedIn, retrieved 2026]. The core product under development aims to produce a Spatial Inflammation Vital Sign™ (SIVS™), a longitudinal index offered alongside a $65,000 turnkey clinic package that includes hardware, software, and an Outcome-as-a-Service dashboard [VITAEUM, retrieved 2026]. Capitalization is not publicly disclosed; investors should request the cap table directly, though the company is reported to be actively raising a pre-seed round. Over the next 12-18 months, the critical watchpoints are the progression of its claimed FDA regulatory pathway and the transition from a conceptual platform to deployed clinic installations with validated user data. Single-source, plausible -- Core claims sourced from company materials; founder background partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed

The Company in Brief

From the public record

VITAEUM was founded in February 2022 by Mike Maunu, who serves as the company's Chief Executive Officer and Chief Science Officer [VITAEUM, retrieved 2026]. The company is incorporated in the United States, with a registered address in Sheridan, Wyoming, and its operational headquarters listed in Scottsdale, Arizona [Prospeo, retrieved 2026][LinkedIn, retrieved 2026]. The founding narrative centers on establishing a standardized measurement infrastructure for a field the company terms "spatial physiology." This effort is positioned as a direct response to a perceived gap in longitudinal, non-diagnostic physiologic assessment tools for clinical, performance, and wellness applications [VITAEUM, retrieved 2026].

Key development milestones are self-reported and focus on intellectual property and regulatory strategy. The company states it has filed five provisional patents and that its core Predictive Infrared Intelligence™ (PII™) technology is patent-pending [vitaeumwellness.com, retrieved 2026]. A significant claimed milestone is the submission of two FDA Q-Submissions and the initiation of a De Novo classification pathway, though these regulatory steps have not been independently verified by public agency records [Gust, retrieved 2026]. The company began publicly promoting a turnkey clinic package for $65,000 in 2026, marking a shift from pure platform development to a defined commercial offering [VITAEUM, retrieved 2026].

Single-source, plausible -- Key dates and founder role confirmed by company sources; regulatory and incorporation details are company-reported and not independently corroborated.

What They Have Built

Mixed sourcing

VITAEUM’s core proposition is a hardware-plus-software system designed to convert infrared imaging into a standardized, longitudinal measurement of physiological state. The company’s public materials describe a platform still in development, centered on a patent-pending methodology it calls Predictive Infrared Intelligence (PII) [VITAEUM, retrieved 2026]. This system is intended to be device-agnostic, processing data from infrared cameras to generate a non-diagnostic metric called the Spatial Inflammation Vital Sign (SIVS) [VITAEUM, retrieved 2026]. The SIVS is framed as a vital sign for spatial physiology, quantifying changes in thermal patterns over time for use in clinical, performance, and wellness monitoring.

For prospective buyers, the company markets a tangible, turnkey clinic package. This offering is priced at $65,000 and includes a specific hardware component called the ThermaLens, integration for heart rate variability (HRV) data, scanning protocols, patient report templates, and access to an Outcome-as-a-Service dashboard [VITAEUM, retrieved 2026]. This bundle suggests the product is positioned for clinic operators seeking to add a new service line. A separate consumer-facing wellness app is also promoted, with explicit disclaimers that it is a "wellness-only, non-medical platform" making no diagnostic claims [VITAEUM, retrieved 2026].

The technological and regulatory claims underpinning the platform are ambitious but primarily self-reported. The company states it utilizes FDA-cleared infrared technology and that its PII methodology is patent-pending [vitaeumwellness.com, retrieved 2026]. A company profile on Gust claims two accepted FDA Q-Submissions and an active De Novo regulatory pathway, alongside five provisional patents [Gust, retrieved 2026]. These regulatory steps, if verified, would represent a significant technical moat, but they are not yet independently corroborated by public agency filings or third-party reports.

Single-source, plausible -- Product details are drawn from company websites and profiles; key regulatory claims are unverified.

Market Size and Demand

From the public record The market for standardized, longitudinal physiological measurement is emerging not as a single product category but as an infrastructure need, driven by a shift toward preventative care and the search for reliable biomarkers of aging.

Demand is anchored by two converging trends. First, the longevity and precision medicine sectors require objective, repeatable metrics to track the efficacy of interventions over time, a gap that has attracted significant public funding. The Advanced Research Projects Agency for Health (ARPA-H) has committed approximately $144 million to studies aimed at slowing aging and extending quality of life, with a core goal of validating a biomarker that tracks aging, responds to interventions, and can pass regulatory muster [Science, retrieved 2026]. Second, healthcare systems are increasingly incentivized to move from episodic, diagnostic care to continuous, outcome-based models, creating a need for non-diagnostic tools that can inform proactive decision-making without triggering complex medical device regulations.

Adjacent and substitute markets provide context for potential scale. The broader digital health monitoring market, encompassing wearable devices and remote patient monitoring platforms, serves as an analogous commercial landscape. The market for infrared thermography in medical and wellness applications, while smaller and more specialized, represents the direct technological substitute. The company's positioning suggests it aims to carve out a new segment at the intersection of these spaces: a regulated-aligned measurement infrastructure, rather than a consumer gadget or a point-of-care diagnostic tool.

Regulatory and macro forces are pivotal. The company's narrative is heavily weighted on navigating the U.S. Food and Drug Administration (FDA) pathway, claiming an active De Novo classification effort and accepted Q-Submissions [Gust, retrieved 2026]. Success in defining a new regulatory category for 'spatial physiology' would be a significant barrier to entry but also a primary execution risk. Macro tailwinds include the aging global population, rising chronic disease burdens, and the growth of value-based care contracts, all of which increase the economic appeal of tools that promise earlier intervention and more precise outcome tracking.

Market Segment	Cited Size / Activity	Source
Longevity Biomarker Research	~$144M in ARPA-H funding	[Science, retrieved 2026]
Measurement Gap in Longevity Science	~$200M ARPA-H commitment (company claim)	[Gust, retrieved 2026]

The sizing data is limited and points to early-stage, research-focused capital allocation rather than a mature commercial market. The $144 million figure from a scientific publication is a matter of public record, while the larger $200 million commitment is cited solely by the company. This suggests the total addressable market remains largely undefined and is currently being constructed through foundational research grants and potential future procurement.

Single-source, plausible -- One public research funding figure is corroborated; other sizing claims are company-sourced.

Who Else Is Fighting for This

Mixed sourcing

VITAEUM is positioning itself not as a direct replacement for existing diagnostic devices, but as a new measurement infrastructure layer for a category it calls spatial physiology, a move that places it in a competitive gray area between established medical imaging, wellness wearables, and unproven biomarker platforms.

The competitive analysis proceeds on the basis of inferred category definitions.

• Medical-grade thermography. The market for FDA-cleared infrared imaging systems is occupied by companies like FLIR Systems (now Teledyne FLIR) and AIM Infrared, which sell hardware for clinical and industrial applications. These incumbents provide the foundational technology but do not offer the longitudinal, standardized data platform or the specific non-diagnostic physiologic index (SIVS) that VITAEUM is proposing. Their edge is entrenched hardware distribution and regulatory history; VITAEUM's claimed edge is a software-defined, outcome-focused layer built on top of such hardware.
• Wearable biomarker platforms. Companies like Levels (continuous glucose monitoring), Oura (sleep and recovery), and Whoop (strain and recovery) have established consumer and professional wellness channels for longitudinal physiologic data. These competitors own the direct-to-consumer relationship and have significant brand traction. VITAEUM's differentiator is its focus on spatial, whole-body infrared imaging rather than point-sensor data, and its explicit targeting of clinical and institutional procurement, a channel these wellness-first companies have not deeply penetrated.
• Longevity biomarker startups. The broader field of aging biomarkers includes companies developing blood-based epigenetic clocks (e.g., TruDiagnostic) or other multi-omics panels. These operate in the diagnostic or direct-to-consumer lab test space. VITAEUM's spatial inflammation metric seeks to occupy a different, non-invasive, and more frequent measurement niche, though it must prove its correlation with established gold-standard biomarkers to gain credibility.

Where VITAEUM claims a defensible edge today is in its regulatory framing and bundled offering. The company's public narrative emphasizes an active De Novo pathway and accepted FDA Q-Submissions [Gust], a process that, if successfully navigated, could create a regulatory moat around its specific non-diagnostic claim set. This edge is perishable, however, as it relies entirely on unverified self-reported progress and eventual FDA approval. A second claimed edge is the integrated turnkey package,hardware, software, protocols, and dashboard,priced at $65,000 for clinics [VITAEUM]. This bundles elements that competitors sell separately, potentially lowering the adoption friction for a clinic owner. The durability of this edge depends on execution and whether larger hardware manufacturers decide to offer a similar integrated software suite.

The company is most exposed in two areas. First, it lacks the capital and brand recognition of established players in either the medical device or wellness wearable sectors. A company like Apple, with its deep resources and focus on health, could theoretically decide to integrate similar spatial sensing into future hardware, leveraging its massive distribution to define the category. Second, VITAEUM's go-to-market relies on convincing clinics to adopt a new, unproven standard of measurement. This faces headwinds from the inertia of existing reimbursement codes and clinical workflows built around traditional vital signs and diagnostic imaging.

The most plausible 18-month competitive scenario involves validation through early clinical deployments. If VITAEUM can secure published pilot studies showing correlation between its SIVS metric and clinical outcomes in, for example, physical therapy or chronic inflammation management, it becomes a "winner if data validates." This would attract partnership interest from larger pharmaceutical or medical device companies looking for digital endpoints. Conversely, if the company fails to move beyond its current marketing materials and does not close its ongoing funding round, it becomes a "loser if execution stalls." In that case, the space would likely be defined by a better-funded competitor, perhaps one emerging from the academic research sector, that replicates the infrastructure concept with stronger clinical validation and a clearer path to reimbursement.

Single-source, plausible -- Competitive analysis is inferred from company positioning and public market segments; no direct competitor names are confirmed in sources.

Opportunity

From the public record

The prize for VITAEUM is a foundational position in the emerging spatial physiology market, translating a novel, non-diagnostic measurement layer into a standardized infrastructure for longevity research, clinical trials, and proactive care.

The headline opportunity is that VITAEUM could become the default, regulated-aligned measurement infrastructure for spatial physiology. This outcome is reachable not because of current scale, but because of the company's explicit regulatory wedge and its framing as a solution to a recognized, funded problem. The company claims to have two accepted FDA Q-Submissions and an active De Novo pathway, positioning itself to define a new regulatory category rather than compete within an existing one [Gust, retrieved 2026]. This is coupled with a direct alignment with a major government initiative, as the company notes that "ARPA-H just committed ~$200M to solve the measurement gap in longevity science. VITAEUM has the architecture" [Gust, retrieved 2026]. If successful, this path could see VITAEUM's Spatial Inflammation Vital Sign™ (SIVS™) become a required, standardized metric for clinical studies and health system procurement, creating a defensible platform position.

Growth from a pre-seed startup to that infrastructure role would likely follow one of several concrete scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory Standard Bearer	The FDA grants a De Novo classification for SIVS™ as a non-diagnostic physiologic index, making it a de facto standard for longitudinal studies.	Successful navigation of the active De Novo pathway and publication of validation data.	The company's public claims of an active De Novo pathway and accepted Q-Subs suggest a focused regulatory strategy is already underway [Gust, retrieved 2026].
Pharma & Longevity Research Partner	VITAEUM becomes the measurement partner for clinical trials targeting aging biomarkers and chronic disease interventions.	A partnership with a top-20 pharma company or a research institution funded by ARPA-H's longevity initiative.	The company's architecture is explicitly pitched to address the measurement gap ARPA-H is funding, creating a logical entry point for research collaborations [Gust, retrieved 2026].
Clinic-in-a-Box Scale	The $65,000 turnkey clinic package gains adoption in functional medicine, sports performance, and wellness clinics, creating a distributed data network.	Securing a multi-clinic roll-out agreement with a national franchise or group purchasing organization.	The fully priced, bundled offering is already being marketed directly to clinic buyers, indicating a clear commercialization path exists [VITAEUM, retrieved 2026].

Compounding for VITAEUM would manifest as a data and distribution flywheel. Each new clinic deployment or research partnership would generate more longitudinal, standardized physiologic scans, directly improving the proprietary AI models underpinning Predictive Infrared Intelligence™. The company asserts that every platform interaction "generates revenue, produces standardized physiological data, [and] extends a longitudinal record of change" [LinkedIn, retrieved 2026]. This creates a dual moat: the dataset becomes more valuable and unique over time, while the established SIVS™ metric, if recognized, creates switching costs for researchers and clinicians who build protocols around it. Early evidence of this flywheel is not yet public, but the product architecture is designed to enable it.

The size of the win, should the Regulatory Standard Bearer scenario play out, can be contextualized by looking at the valuation of companies that have successfully created new measurement categories in adjacent fields. For example, Dexcom, which established continuous glucose monitoring as a new standard of care, currently holds a market capitalization exceeding $40 billion. While VITAEUM's non-diagnostic focus and earlier stage present a different risk profile, the precedent shows that defining and owning a new, essential physiologic metric can support enterprise-scale value creation. A more immediate comparable might be the acquisition multiples for specialized medical data platforms, but no such transaction is cited for this specific niche. The ARPA-H commitment of approximately $200 million to solve the longevity measurement gap provides a tangible, near-term TAM anchor for the initial infrastructure opportunity (scenario, not a forecast) [Gust, retrieved 2026].

Single-source, plausible -- The core opportunity framing relies on company claims regarding regulatory progress and market alignment, which are not independently verified. The ARPA-H funding commitment is corroborated by external reporting [Science, retrieved 2026].

Sources

From the public record

1. [VITAEUM, retrieved 2026] Spatial physiology infrastructure building a non-diagnostic measurement layer for longevity, pharma, clinical, and wellness. | https://www.vitaeum.us/

2. [LinkedIn, retrieved 2026] Founder/ CEO & CSO at VITAEUM™ | Defining a New Regulatory Category for Spatial Physiology | https://www.linkedin.com/in/mikemaunu/

3. [VITAEUM, retrieved 2026] VITAEUM - Predictive Infrared Intelligence | https://www.vitaeum.us/foundation

4. [VITAEUM, retrieved 2026] Market - VITAEUM - Predictive Infrared Intelligence | https://www.vitaeum.us/market

5. [LinkedIn, retrieved 2026] VITAEUM | LinkedIn | https://www.linkedin.com/company/vitaeum

6. [Prospeo, retrieved 2026] VITAEUM Email Formats | https://prospeo.io/c/vitaeum-email-format

7. [vitaeumwellness.com, retrieved 2026] Step 1: Watch This Free Training Right Now | https://www.vitaeumwellness.com/wellness

8. [Gust, retrieved 2026] VITAEUM Gust Profile | https://gust.com/companies/vitaeum

9. [Science, retrieved 2026] ARPA-H commits ~$144M to studies that slow aging and extend quality of life | https://www.science.org/content/article/arpa-h-commits-144-million-studies-slow-aging-and-extend-quality-life